Results 31 to 40 of about 102,224 (277)

Erythrocytes as Carriers of Therapeutic Enzymes. [PDF]

, 2020
Therapeutic enzymes are administered for the treatment of a wide variety of diseases. They exert their effects through binding with a high affinity and specificity to disease-causing substrates to catalyze their conversion to a non-noxious product, to ...
Bax, BE
core   +1 more source

TYMP (thymidine phosphorylase) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on TYMP (thymidine phosphorylase), with data on DNA, on the protein encoded, and where the gene is implicated.
Bijnsdorp, IV, Peters, GJ
openaire   +2 more sources

Mitochondrial neurogastrointestinal encephalomyopathy: approaches to diagnosis and treatment [PDF]

, 2020
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare disease caused by mutations in TYMP, the gene encoding for the enzyme thymidine phosphorylase.
Bax, BE
core   +1 more source

Synthesis of new isoquinoline-base-oxadiazole derivatives as potent inhibitors of thymidine phosphorylase and molecular docking study. [PDF]

Sci Rep, 2019
Here in this study regarding the over expression of TP, which causes some physical, mental and socio problems like psoriasis, chronic inflammatory disease, tumor angiogenesis and rheumatoid arthritis etc.
Zaman K, Rahim F, Taha M, Wadood A, Shah SAA, Ahmed QU, Zakaria ZA.   +6 more
europepmc   +2 more sources

Thymidine phosphorylase and uridine phosphorylase of Lactobacillus casei [PDF]

FEMS Microbiology Letters, 1988
Crude extracts of Lactobacillus casei, were found to possess both thymidine phosphorylase and uridine phosphorylase activities, which were associated with a single sucrose gradient band. However, using dye ligand chromatography (Green A), two enzymatic fractions were obtained each of which possessed mainly one of these activities.
Y. Avraham, J. Yashphe, N. Grossowicz
openaire   +2 more sources

Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect. [PDF]

Cell Death Dis, 2019
Tumor progression is dependent on metabolic reprogramming. Metastasis and vasculogenic mimicry (VM) are typical characteristics of tumor progression. The relationship among metastasis, VM, and metabolic reprogramming remains unclear.
Zhang Q, Qin Y, Zhao J, Tang Y, Hu X, Zhong W, Li M, Zong S, Li M, Tao H, Zhang Z, Chen S, Liu H, Yang L, Zhou H, Liu Y, Sun T, Yang C.   +17 more
europepmc   +2 more sources

Efficient Biocatalytic Synthesis of Dihalogenated Purine Nucleoside Analogues Applying Thermodynamic Calculations [PDF]

, 2020
The enzymatic synthesis of nucleoside analogues has been shown to be a sustainable and efficient alternative to chemical synthesis routes. In this study, dihalogenated nucleoside analogues were produced by thermostable nucleoside phosphorylases in ...
Giessmann, Robert T., Kaspar, Felix, Klare, Hendrik F. T., Kurreck, Jens, Neubauer, Peter, Paulick, Katharina, Röhrs, Viola, Wagner, Anke, Westarp, Sarah, Yehia, Heba   +9 more
core   +1 more source

Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer

BMC Cancer, 2010
Background Biliary tract cancers have limitations in information about different location-related pathogenesis and clinico-pathological characteristics.
You Young, Kim Dong-Goo, Chung Eun-Seon, Lee Myung, Won Hye, Hong Tae, Lee In-Seok   +6 more
doaj   +1 more source

Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

BMC Cancer, 2011
Background To assess the role of Thymidine Phosphorylase and β-tubulin III in clinical outcome of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Shen Lin, Li Yan-yan, Yu Jing-wei, Lu Ming, Gao Jing   +4 more
doaj   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source